Incyte has reached a settlement with the Centers for Medicare & Medicaid Services (CMS) regarding rebate criteria for its eczema and vitiligo treatment Opzelura, according to a
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
A favorable regulatory resolution with federal health authorities is clearing the way for Incyte’s Opzelura cream to reach…
In hopes of challenging Incyte’s topical JAK inhibitor Opzelura, Pfizer is headed to regulators with results from a pair of…
The Federal Trade Commission may be winding down its ongoing insulin case against the three largest pharmacy benefit managers, as…
The top pharmacy benefit manager (PBM) in the U.S., CVS Caremark, will
Incyte (Nasdaq: INCY) oggi ha annunciato che il Comitato per i prodotti medicinali per uso umano (CHMP) dell'Agenzia Europea per…
Elevance Health is suing the feds over its recent recalculations for the 2026 Medicare Advantage star ratings. | Elevance Health…
